

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-7 (cancelled)

Claim 8 (new) An acid addition salt of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (Imatinib) selected from the group consisting of a D-tartrate salt, a L-tartrate salt, a succinate salt and a malonate salt.

Claim 9 (new) An acid addition salt according to claim 1 selected from the group consisting of imatinib D-tartrate and imatinib malonate.

Claim 10 (new) A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an acid addition salt of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide (Imatinib) selected from the group consisting of a tartrate salt, a succinate salt and a malonate salt.